Childhood Vaccination Coverage Statistics, England, 2022-23

Schedule for 6-in-1(DTaP/IPV/Hib/HepB)

_{4. https://www.gov.uk/government/publications/hexavalent-combination-vaccine-programme-guidance}

• Coverage in England remains  below the 95% target in 2022-23.
• In 2022-23, 91.8% of children were reported to have completed their primary course of 3 doses at 12 months.
• Coverage in 2021-22 was also 91.8%. There has been a general downward trend in coverage for this vaccination since the peak of 94.7% reported in 2012-13.

DTaP/IPV/Hib/HepB

Regional coverage at 12 months

• In 2022-23, 8 of 9 regions exceeded 90% coverage. 1 region (North East) exceeded the national target of 95%.
• London had the lowest coverage (87.6%) and was 7.6 percentage points lower than the North East which had the highest coverage (95.1%)

• 28 LAs (out of 149) have coverage levels of 95% and above. With the highest coverage reported for Sunderland at 97.6%.
• 39 LAs reported coverage of less than 90%. 24 of these LAs were in London.
• 7 LAs had coverage below 85%, 5 of those are in London.

DTaP/IPV/Hib/HepB

National coverage at 24 months

DTaP/IPV/Hib/HepB

Regional coverage for 6-in-1 at 24 months

• In 2022-23, 8 out of 9 regions reached 90% coverage. 2 regions met the national target of 95%.
• London has the lowest regional coverage (87.4%) and was 8.7 percentage points lower that the North East which has the highest coverage (96.1%). None of the London LAs met the 95% target, 25 of 32 LAs were below 90% (see Data Table 9a for LA level data).

‘5-in-1’ or '6-in-1' vaccine - DTaP/IPV/Hib

Children in the 5 year cohort were born between 1 April 2017 and 31 March 2018.

The vaccination schedule changed from the 5-in-1 to the 6-in-1 in August 2017, therefore, children in this cohort received either the 5-in-1 or the 6-in-1 vaccination, depending on when they were vaccinated.

Many, but not all children will have received the 6-in-1 vaccination. All components present in the 5-in-1 are present in the 6-in-1, so all vaccinated children in this cohort have received the 5-in-1 component.

National coverage at 5 years

• In 2022-23, coverage for the 5-in-1 vaccine at 5 years was 93.2%, 1.2 percentage points lower than the 94.4% coverage reported in 2021-22.
• Coverage is now at it's lowest since 2008-09, having previously met the 95% target for 10 years between 2011-12 and 2020-21.

‘5-in-1’ vaccine - DTaP/IPV/Hib

Regional coverage at 5 years

• In 2022-23, coverage was above 90% in 8 of 9 regions.
• South West was the only region to exceed the 95% target (95.6% for 2022-23).
• London had the lowest coverage (88.1%), which was 7.5 percentage points lower than the South West.

National and regional coverage

Children should receive their DTaP/IPV pre-school booster from 3 years and 4 months or soon thereafter. (This vaccine is given to children who have received a 3 dose course of the 5-in-1 vaccination).

National coverage at 5 years

• In 2022-23, coverage was 83.3%. This represents a decrease from 2021-22, when coverage was 84.2%
• Coverage was highest in 2012-13, at 88.9%.

National coverage of MMR1 at 24 months

• In 2022-23, 89.3% of children received their 1st dose of the MMR vaccine. This compares with 89.2% in 2021-22 and is the second consecutive year that coverage has been below 90%.
• Coverage previously exceeded 90% for 10 years between 2011-12 and 2020-21.

Regional coverage of MMR1 at 24 months

• In 2022-23, 6 of 9 regions reached 90% coverage. No region met the national target of 95%.
• London had the lowest coverage (82.4%) and was 12.2 percentage points lower than the North East with the highest coverage (94.6%).

Upper tier local authority (LA) coverage at 24 months

• In 2022-23, 9 LAs (out of 149) had coverage levels of 95% and above.
• Coverage of less than 90% was reported for 67 LAs, including 31 of 32 London LAs.

National MMR1 coverage at 5 years

• In 2022-23, coverage was 92.5%, this represents a decrease from 2021-22, when coverage was 93.4%.
• The 95% target was reached for the first and only time in 2016-17 and consistently decreased since then.

Regional MMR1 coverage at 5 years

• In 2022-23, the North East was the only region to meet the target of 95%.
• Coverage in London is below 90%.

National coverage at 12 months

In 2022-23, 88.7% of children in England were reported to have received 2 doses of the rotavirus vaccine as measured at 12 months, a decrease of 1.2 percentage points from 89.9% in 2021-22.

Rotavirus vaccine coverage is now at it's lowest level since data became available in 2016-17.

Regional coverage at 12 months

• Coverage in all regions declined compared to the previous year.  Coverage in 4 regions was above 90%, however none achieved 95%.
• Coverage was 8.4 percentage points lower in London (the region with lowest coverage at 84.4%) compared to the North East, the region with the highest coverage (92.9%)

National coverage at 12 months (PCV primary course):

• PCV data for the 12-month cohort was not available for 2020-21. This is due to the change in the vaccine schedule and how the vaccine is recorded. See Appendix L for details.
• Coverage was 93.7% in 2022-23 a decrease of 0.1 percentage points from 2021-22. This compares to 93.2% in 2019-20 when a two dose schedule was offered, suggesting improved coverage with a single dose.

 National coverage at 24 months (PCV booster):

• In 2022-23, 88.5% of children had completed a booster course of PCV, a decrease from 89.3% the previous year and a continuation of the downward trend since the peak of 92.5% in 2012-13.

Regional coverage at 24 months (booster)

• In 2022-23, 6 of 9 regions reached 90% coverage. No region exceeded the national target of 95%.
• Coverage in England was below the 95% target in 2022-22, 2021-22 and 2020-21.
• London had consistently lower coverage in those three years and in 2022-23, at 80.4%, was 13.6 percentage points lower than the North East with the highest coverage (94.0%)

National coverage at 24 months

• Coverage in England remains below 90% for a second year, having declined consistently since a peak of 92.7% in 2012-13.
• In 2022-23, 88.7% of children in England were reported to have received the combined Hib/MenC vaccine.
• This is a decrease of 0.3 percentage points from the 2021-22 value of 89.0%.

Regional coverage at 24 months

• In 2022-23, 6 out of 9 regions reached 90% coverage. No region reached the national target of 95%.
• In 2022-23, coverage was lowest at 81.3% in London, 12.7 percentage points lower than the North East which had the highest coverage (94%).

National and Regional coverage at 12 months

• In 2022-23, 91.0% of children in England received 2 doses of the Men B vaccine, a decrease of 0.5% from 91.5% in 2021-22.
• In 2022-23, 8 of 9 regions reached 90% coverage, no region achieved the 95% national target.
• London had the lowest coverage at 86.4%, 8 percentage points lower than the North East at 94.4%.

Vaccine summary:

• In 2022-23, coverage was 87.6%, this represents a decrease of 0.4% from 2021-22, when coverage was 88.0%
• 3 of 9 regions reached 90% coverage, while no regions achieved 95% coverage.
• London had the lowest coverage (79.4%) and was 14 percentage points lower than the North East with the highest coverage (93.4%).

The table below displays the annual 2022-23 coverage values for the 4 UK countries. UK time series data (from 2009-10 to 2022-23) can be accessed in the interactive dashboard: http://bit.ly/child_vacc_stats_annual 
Quarterly UK and country level vaccine coverage statistics are published in the quarterly COVER Health Protection Report by UKHSA⁵.   

Source: COVER – UKHSA, NHS England. See Data Tables 5a, 5b and 5c.

Values highlighted in bold represent those at or above the 95% target. (If a number rounds up to 95.0%, but the true figure is below 95.0%, the number is not in bold)

Links to vaccine statistics publications for Northern Ireland, Scotland and Wales can be found in the Quality Statement (Coherence and Comparability section).

^{5. https://www.gov.uk/government/statistics/cover-of-vaccination-evaluated-rapidly-cover-programme-2021-to-2022-quarterly-data}

In addition to the routine vaccines listed in this report, there are 2 selective neonatal vaccination programmes.

_{*  ‘At Risk’ infants: born to mothers who are chronically infected with Hepatitis B  (HBV) or to mothers who have had acute hepatitis B during pregnancy. Full details here: https://www.gov.uk/government/publications/hexavalent-combination-vaccine-programme-guidance}

_{** Data for BCG collected through COVER were included for the first time in 2016-17}

_{*** At risk infants:}

 _{1. All infants (aged 0 to 12 months) with a parent or grandparent who was born in a country where the annual incidence of Tuberculosis (TB) is 40/100,000 or greater.
 2. All infants (aged 0 to 12 months) living in areas of the UK where the annual incidence of TB is 40/100,000 or greater}

Data for 2 selective vaccination programmes are published within the data tables, BCG and Hepatitis B.

BCG data can be found in Table 11a of the accompanying data tables. Coverage and eligible population data are published for the first time for all LAs, not just those running a universal vaccination programme. Data is published at regional and national level. Coverage is assessed at age 3 months, previously coverage was assessed at 12 months. These data were collected and published in this format for the first time in 2022-23, and are badged as experimental statistics.

HepB data can be found in Tables 11b and 11c for children aged 12 months and 24 months old respectively. Data is only published at LA level, there is no aggregation to regional and national level due to suppression.

More information on BCG can be found in the Tuberculosis report published by UKHSA  

Appendix E of the accompanying Appendices document has more information.

Influenza vaccine

• During the 2022-23 winter season (1 September 2022 to 31 March 2023), all GP practices in England were asked to offer the influenza (seasonal flu) vaccine to all registered children aged 2 and 3 years.
• School age children aged 4 to 11 years are also vaccinated, but this data is not presented in this report⁶.
• Age is defined as age on 31 August 2022
• Data is collected for the period 1 September 2022 to 28 February 2023.
• Regional data for 2 and 3 year olds is presented below.
• For further information, see the UKHSA report, which contains additional information, such as a coverage broken-down by children ‘in a clinical risk group’ and ‘not in a clinical risk group’
• https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptake:-figures
• Information on recommended components of vaccine: https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations

_{6.https://www.gov.uk/government/statistics/seasonal-influenza-vaccine-uptake-in-gp-patients-winter-season-2021-to-2022}

During the 2022-23 winter season (1 September 2022 to 31 March 2023), all GP practices in England were asked to offer the influenza (seasonal flu) vaccine to all registered children aged 2 or 3 years. Coverage data shown was collected for the period 1 September 2022 to 28 February 2023.

Percentage of children vaccinated at 2 and 3 years of age

• In 2022-23, influenza vaccination coverage was 43.7% for the combined 2 and 3 years age group.
• This is a decrease of 6.4 percentage points from 2021-22, when coverage for the combined 2 and 3 year age group was 50.1%
• This is also a decrease of 13.0 percentage points compared to 2020-21, where the figure was 56.7%
• Coverage declined in all regions in 2022-23

Note: Data is final end of season and represents 98.4% of all GP practices in England responding to the February 2022 Child GP Flu Survey (green) compared with 97.1% of practices in the same survey month in 2021-22. For further info. see Appendix B
Read the UKHSA report.